05:49pm Sunday 22 October 2017

Study of incidence of transmissible disease in ART patients shows EU requirement for screening at each donation to be unnecessary

Ms Ciara Hughes, Senior Embryologist at Human Assisted Reproduction Ireland (HARI), Dublin, told the conference that, under the new Irish legislation, screens for HIV 1 and 2 and hepatitis B and C have to be carried out within 30 days of the start of each ART cycle. Prior to the transposition of the EU Tissues and Cells Directive into Irish law, these diseases were routinely screened for in patients at HARI and the clinic’s policy was to have these screens performed within six months of the start of a couple’s cycle of treatment.

“Most of these couples are in a stable relationship, and we believed that they were at minimal risk of contracting a communicable disease once the initial screen had showed them to be negative,” said Ms Hughes. “However, we had no definitive proof of this and it is why we decided to carry out our study.”

The researchers looked at screening results over a ten-year period from 1023 couples who had returned to the HARI clinic for testing after a 180 day quarantine of their surplus frozen embryos and gametes. These couples had been clear on their first screening. Following re-testing, the results were exactly the same – no seroconversion (the development of specific antibodies in response to infection) had taken place in the intervening period. They also examined the screening results of 555 male oncology patients who were clear on first screening and returned for 180 days follow-up testing. Once again, all of them showed the same viral screen status and remained clear of infection.

“Since the introduction of the new testing requirement, we have carried out 17,494 viral screen tests either before therapy or within 30 days of egg collection and have not come across a single seroconversion,” said Ms Hughes. “While I understand that safeguards are necessary to prevent the transmission of disease through the use of human tissue, assisted reproduction is not the same as organ donation or blood transfusion. The main difference is that in IVF the donation is to your cohabiting partner, whereas in tissue donation it is to an unknown person.

“Our research has proved what we already suspected; that there is negligible risk of seroconversion in this group of patients. Given the physical, financial, and emotional investment that each couple makes in undergoing a cycle of treatment, it is unjustifiable to request testing at the time of each donation in order to assess such a minimal risk.”

In requiring testing within 30 days of each cycle, Ireland has interpreted the Directive in a particularly restrictive way. Other countries such as Denmark have introduced more relaxed laws, which only require testing every two years. Since the introduction of the new law, all couples in Ireland have to pay, on average, an additional €160 per cycle of IVF or ICSI. This could cost in the region of €1.5 million per year, said Ms Hughes. At the clinic couples could have up to three cycles of treatment per year, and depending on the timing, this could mean each couple paying an additional €480 per year on top of the treatment cost.

The legislation should be revised in order to factor in the unproven risks and to take into account individual patient needs, said Ms Hughes. “Our study is, to our knowledge, the first to carry out a risk assessment of the need for repeat viral screening in ART patients. Armed with this knowledge, a review of the European and Irish legislation in relation to assisted reproduction should be undertaken to avoid a lot of unnecessary costs, both financial and emotional, to couples undergoing ART,” she concluded.

 


Poster no: P-315 (Poster Village, Hall 6)

Notes for editors:

In a position statement, ESHRE concludes that, with 900,000 assisted reproduction treatments such as IVF and intrauterine inseminations per year in Europe, screening both partners before each treatment could lead to an annual cost of over €140 million. These figures do not include the additional overhead costs related to administration, personnel and documentation that the hospitals would have to bear. Such an interpretation of the EU Directive would have substantial implications for the cost of fertility treatments in Europe. ESHRE’s position paper can be found at: http://www.eshre.eu/ESHRE/English/Guidelines-Legal/ESHRE-Position-Papers/page.aspx/942

French version (pdf)

Italian version (pdf)

Spanish version (pdf)

 

Further information:

In English and French:
Mary Rice:
Tel: +33 (0)3 21 82 54 44
Mobile: +33 (0)6 68 93 06 50
Email: mary@mrcommunication.org

 

In English:
Emma Mason
Tel: +44 (0) 1376 563090
Mobile: +44 (0) 7711 296 986
Email: wordmason@mac.com

In English, German, Spanish, French, Swedish

Hanna Hanssen
Tel: + 32 (0)2 269 09 69 (ESHRE Central Office in Brussels)
Mobile: + 32 (0) 473 35 33 81
Email: hanna@eshre.eu

In Italian and English
Elisa Marcellini
Tel: +39 (0)2 76 11 51 47
Mobile: +39 340 868 96 90
Email: e.marcellini@mdemmedi.com

 

Press Office: (Sunday 27 June – Wednesday 30 June)
Mary Rice, Emma Mason, Hanna Hanssen, Elisa Marcellini


Share on:
or:

MORE FROM Female Reproductive

Health news